Skip to content

Beneficial Effect of Xylose Consumption on Postprandial Hyperglycemia

Beneficial Effect of Xylose Consumption on Postprandial Hyperglycemia in Subjects With Normal Glucose Level and Impaired Fasting Glucose

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02654301
Enrollment
80
Registered
2016-01-13
Start date
2014-06-30
Completion date
2015-02-28
Last updated
2016-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postprandial Hyperglycemia

Keywords

Xylose, prediabetes, postprandial hyperglycemia, glucose

Brief summary

The present study determined the effect of Xylose consumption on postprandial hyperglycemia in normal (n=25) and hyperglycemic subjects (n=50).

Detailed description

In this double-blind crossover designed study, Participants were randomly assigned to consume a sucrose drink (Control, sucrose 50g + deionized water 100g) or a sucrose drink additionally containing 5 g (Test 1, sucrose : xylose = 10:1), 3.33 g (Test 2, sucrose : xylose = 15:1) or 2.5 g (Test 3, sucrose : xylose = 20:1) of D-xylose with a week interval.

Interventions

DIETARY_SUPPLEMENTTest 1

sucrose : xylose = 10:1, sucrose 50 g + xylose 5 g + deionized water 95 g

DIETARY_SUPPLEMENTTest 2

sucrose : xylose = 15:1, sucrose 50 g + xylose 3.33 g + deionized water 96.67 g

DIETARY_SUPPLEMENTTest 3

sucrose : xylose = 20:1, sucrose 50 g + xylose 2.5 g + deionized water 97.5 g

DIETARY_SUPPLEMENTControl

sucrose 50 g + deionized water 100 g

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

1\) healthy subject or Impaired fasting glucose (fasting serum glucose between 100 and 125 mg/dL)

Exclusion criteria

1. history of taking an insulin-injection or oral hypoglycemic agents 2. evidence of alcohol abuse or alcoholism 3. pregnancy or breast feeding 4. chronic gastrointestinal disorder 5. seriously abnormal liver or renal function 6. an occupation at risk of death when hypoglycemia occurs

Design outcomes

Primary

MeasureTime frame
Change of serum glucose levelsa week interval

Secondary

MeasureTime frame
Change of serum insulin levelsa week interval
Change of serum C-peptide levelsa week interval

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026